Last reviewed · How we verify
Terbutaline Turbuhaler
Terbutaline is a beta-2 adrenergic receptor agonist that works by relaxing the muscles in the airways and increasing air flow to the lungs.
Terbutaline is a beta-2 adrenergic receptor agonist that works by relaxing the muscles in the airways and increasing air flow to the lungs. Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Terbutaline Turbuhaler |
|---|---|
| Also known as | Bricanyl Turbuhaler |
| Sponsor | AstraZeneca |
| Drug class | Beta-2 adrenergic receptor agonist |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This is achieved by stimulating the beta-2 adrenergic receptors in the smooth muscle of the bronchial tubes, leading to bronchodilation and improved lung function. This is particularly beneficial for individuals with asthma or chronic obstructive pulmonary disease (COPD).
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremors
- Nervousness
- Headache
- Palpitations
Key clinical trials
- Patient Perspective on Climate Impact of Inhalers (NA)
- Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (PHASE3)
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma (PHASE3)
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. (PHASE3)
- Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2 (PHASE1)
- Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3 (PHASE3)
- Study to Investigate the Efficacy of Symbicort® SMART. (PHASE3)
- To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terbutaline Turbuhaler CI brief — competitive landscape report
- Terbutaline Turbuhaler updates RSS · CI watch RSS
- AstraZeneca portfolio CI